Oxaliplatin (OXAL) is a commonly used chemotherapy for treating colorectal cancer (CRC). A recent genome wide association study (GWAS) showed that a genetic variant (rs11006706) in the lncRNA geneMKX-AS1and partnered sense geneMKXcould impact the response of genetically varied cell lines to OXAL treatment. This study found that the expression levels ofMKX-AS1andMKXin lymphocytes (LCLs) and CRC cell lines differed between the rs11006706 genotypes, indicating that this gene pair could play a role in OXAL response. Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with highMKX-AS1expression status had significantly worse overall survival (HR = 3.2; 95%CI = (1.17–9);p= 0.024) compared to cases with lowMKX-AS1expression status. Alternatively, highMKXexpression status had significantly better overall survival (HR = 0.22; 95%CI = (0.07–0.7);p= 0.01) compared to cases with lowMKXexpression status. These results suggest an association betweenMKX-AS1andMKXexpression status that could be useful as a prognostic marker of response to OXAL and potential patient outcomes in CRC.